Amedisys — Q3 2020 Earnings Presentation
19 slides from Amedisys's earnings presentation, Oct 28, 2020
Slide 1: Amedisys Third Quarter 2020 Earnings Call Supplemental Slides
Amedisys Third Quarter 2020 Earnings Call Supplemental Slides October 29, 2020 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau
Slide 3: Q3 2020 Results
Q3 2020 Results amedisys
Slide 4: Our Key Areas of Focus
Our Key Areas of Focus Strategic areas of focus and progress made during Q3’20 Home Health*: Total same store admissions +5%, Total same store volume +6% Hospice: Admissions +9%, Personal Care: Billable hours / quarter -18% driven by impact of COVID-19 - turnover dropping into Q3 which will result i
Slide 5: Highlights and Summary Financial Results (Adjusted): 3Q 2020
Highlights and Summary Financial Results (Adjusted): 3Q 2020(1) Home Health total same store volume +6%, total same store admissions +5%; Hospice same store admissions +9% Amedisys Consolidated Revenue Growth: +10% EBITDA: $76M (+33%) EBITDA Margin: 14% (+240 bps) EPS: $2.24 (+95%) - non-cash compen
Slide 6: Our revenue sources: 3Q'20
Our revenue sources: 3Q’20 Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed
Slide 7: Home Health and Hospice Segment (Adjusted) – 3Q 2020
Home Health and Hospice Segment (Adjusted) – 3Q 2020(1) Revenue per Episode up 1.8% (sequestration suspension benefit $5M) Y/Y CPV up +$5.08 (+5.5%, raises effective 8/1, health insurance, increase in use of contractors, change in visit mix and lower visit volumes) Visits per Episode decreased 2.5 H
Slide 8: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 200 basis points ($26 million) Year over year G&A increase due to our acquisitions (~$11M), raises, incentive accruals, higher health insurance costs, and investments related to PD
Slide 9: Cost per Visit Components
Components 3Q19 2Q’20 3Q’20 YoY Variance Detail Initiatives Salaries $63.24 $63.03 $64.81 $1.57 YoY increase due to planned wage increases, shift in visit mix and fixed costs (training, PTO, etc.) on lower visits, partially offset by optimization of discipline mix. Sequential increase due to the sam
Slide 10: Driving Top Line Growth
Driving Top Line Growth Growth in all three lines of business impacted by COVID-19 but recovering Home Health Total Volume Hospice ADC Personal Care Total Hours / Quarter
Slide 11: Industry Leading Quality Scores
Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 PREVIEW Quality of Patient Care 4.28 4.27 4.26 4.33 Entities at 4+ Stars 88% 86% 86% 92% Metric JUL 19 Release OCT 19
Slide 12: Hospice Quality: Moving Towards Best-in-Class
Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Hospice Compare HIS and CAHPS reporting currently “frozen” and will resume reporting in Feb 2022
Slide 13: Debt and Liquidity Metrics
Debt and Liquidity Metrics ~Net leverage ~1.1x Net debt defined as total debt outstanding ($314.2M) less cash ($52.9M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($247.6M). Liquidity defined as the sum of cash balance and available revolving line of cr
Slide 14: Cash Flow Statement Highlights
Cash Flow Statement Highlights (1) Q2 and Q3 include benefit of payroll tax deferral (COVID-19 relief) of approximately $20 and $18M Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.
Slide 15: Income Statement Adjustments
Income Statement Adjustments (1) The financial results for the three-month periods ended September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020 and September 30, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAA
Slide 16: 2020 Guidance Update
2020 Guidance Update 6 amedisys
Slide 17: Amedisys 2020 Updated Guidance Ranges
Amedisys 2020 Updated Guidance Ranges Note: Adjusted numbers are ex-CARES Act funds *EPS: Inclusive of $0.72 income tax benefit related to executive stock option exercise Increased Revenue, EBITDA and EPS guidance ranges for FY 2020 2020 Original Guidance 2020 Reinstated Guidance Revenue $2,115M – $
Slide 18: Reimbursement Outlook
Reimbursement Outlook Reimbursement Impact for Home Health and Hospice Home Health Hospice 2020 Final Rule (PDGM – Behavioral Assumptions) (4.36%) Estimated AMED-Specific Impact (2.8%) 2020* Market Basket Update 3.0% Productivity / Other Adjustment (0.4) Estimated Industry Impact +2.6% Estimated AME
Slide 19: Our Path Forward: 2021 & Beyond
Our Path Forward: 2021 & Beyond 2021 & Beyond – The Future Is Very Bright for AMED Entering 2021 with all PDGM cost levers in place Continued strategic acquisitions of Home Health and Hospice assets – Home Health market share absorption strategy delayed until early 2021 due to CARES Act funds FY 202